Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? - PubMed (original) (raw)
Review
Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Julie A Carson et al. J Neurochem. 2002 Apr.
Free article
Abstract
The steady-state level of amyloid beta-peptide (Abeta) represents a balance between its biosynthesis from the amyloid precursor protein (APP) through the action of the beta- and gamma-secretases and its catabolism by a variety of proteolytic enzymes. Recent attention has focused on members of the neprilysin (NEP) family of zinc metalloproteinases in amyloid metabolism. NEP itself degrades both Abeta(1-40) and Abeta(1-42) in vitro and in vivo, and this metabolism is prevented by NEP inhibitors. Other NEP family members, for example endothelin-converting enzyme, may contribute to amyloid catabolism and may also play a role in neuroprotection. Another metalloproteinase, insulysin (insulin-degrading enzyme) has also been advocated as an amyloid-degrading enzyme and may contribute more generally to metabolism of amyloid-forming peptides. Other candidate enzymes proposed include angiotensin-converting enzyme, some matrix metalloproteinases, plasmin and, indirectly, thimet oligopeptidase (endopeptidase-24.15). This review critically evaluates the evidence relating to proteinases implicated in amyloid catabolism. Therapeutic strategies aimed at promoting A,beta degradation may provide a novel approach to the therapy of Alzheimer's disease.
Similar articles
- Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration.
Turner AJ, Fisk L, Nalivaeva NN. Turner AJ, et al. Ann N Y Acad Sci. 2004 Dec;1035:1-20. doi: 10.1196/annals.1332.001. Ann N Y Acad Sci. 2004. PMID: 15681797 Review. - Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.
Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Nalivaeva NN, et al. Curr Alzheimer Res. 2008 Apr;5(2):212-24. doi: 10.2174/156720508783954785. Curr Alzheimer Res. 2008. PMID: 18393806 Review. - Regulation of amyloid beta-peptide levels by enzymatic degradation.
Mukherjee A, Hersh LB. Mukherjee A, et al. J Alzheimers Dis. 2002 Oct;4(5):341-8. doi: 10.3233/jad-2002-4501. J Alzheimers Dis. 2002. PMID: 12446966 - Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O. Hüttenrauch M, et al. J Alzheimers Dis. 2015;44(4):1291-302. doi: 10.3233/JAD-142463. J Alzheimers Dis. 2015. PMID: 25408216 - Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.
Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB. Eckman EA, et al. J Biol Chem. 2006 Oct 13;281(41):30471-8. doi: 10.1074/jbc.M605827200. Epub 2006 Aug 14. J Biol Chem. 2006. PMID: 16912050
Cited by
- Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.
Wang R, Wang S, Malter JS, Wang DS. Wang R, et al. J Alzheimers Dis. 2009;17(3):489-501. doi: 10.3233/JAD-2009-1066. J Alzheimers Dis. 2009. PMID: 19363254 Free PMC article. - Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase.
Walther T, Albrecht D, Becker M, Schubert M, Kouznetsova E, Wiesner B, Maul B, Schliebs R, Grecksch G, Furkert J, Sterner-Kock A, Schultheiss HP, Becker A, Siems WE. Walther T, et al. PLoS One. 2009;4(2):e4590. doi: 10.1371/journal.pone.0004590. Epub 2009 Feb 25. PLoS One. 2009. PMID: 19240795 Free PMC article. - HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes.
Lan X, Xu J, Kiyota T, Peng H, Zheng JC, Ikezu T. Lan X, et al. J Immunol. 2011 Jun 15;186(12):6925-32. doi: 10.4049/jimmunol.1100211. Epub 2011 May 6. J Immunol. 2011. PMID: 21551363 Free PMC article. - Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.
Miners JS, Palmer JC, Tayler H, Palmer LE, Ashby E, Kehoe PG, Love S. Miners JS, et al. Front Aging Neurosci. 2014 Sep 11;6:238. doi: 10.3389/fnagi.2014.00238. eCollection 2014. Front Aging Neurosci. 2014. PMID: 25309424 Free PMC article. Review. - Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
Head E, Lott IT, Wilcock DM, Lemere CA. Head E, et al. Curr Alzheimer Res. 2016;13(1):18-29. doi: 10.2174/1567205012666151020114607. Curr Alzheimer Res. 2016. PMID: 26651341 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources